Paul Henry Huibers, president of Lilly Korea discusses Lilly’s strong double-digit growth following a challenging period of restructuring. Huibers offers his opinion on the pricing difficulties within the Korean market, emphasizing the importance of volume over price. He also concludes that Korea should focus on establishing itself as a leader in the field of stem cell research and gene therapy, rather than playing catch up in the biologics market.
t to survive, a company must drive volume by innovating and delivering better and improved treatments that represent significant value for the payers
